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Objective—Spontaneous preterm birth (SPTB) is a complex condition that is likely a final 
common pathway with multiple possible etiologies. We hypothesized that a comprehensive 
classification system could appropriately group women with similar STPB etiologies, and provide 
an explanation, at least in part, for the disparities in SPTB associated with race and gestational age 
at delivery.
Study Design—Planned analysis of a multicenter, prospective study of singleton SPTB. Women 
with SPTB < 34 weeks were included. We defined 9 potential SPTB phenotypes based on clinical 
data, including infection/inflammation, maternal stress, decidual hemorrhage, uterine distention, 
cervical insufficiency, placental dysfunction, premature rupture of the membranes, maternal 
comorbidities, and familial factors. Each woman was evaluated for each phenotype. Delivery 
gestational age was compared between those with and without each phenotype. Phenotype profiles 
were also compared between women with very early (20.0–27.9 weeks) SPTB vs. those with early 
SPTB (28.0–34.0 weeks), and between African-American and Caucasian women. Statistical 
analysis was by t-test and chi-square as appropriate.
Results—The phenotyping tool was applied to 1025 women with SPTB who delivered at a mean 
30.0 (+/− 3.2) weeks gestation. Of these, 800 (78%) had ≥2 phenotypes. Only 43 (4.2%) had no 
phenotypes. The 281 women with early SPTB were more likely to have infection/inflammation, 
decidual hemorrhage, and cervical insufficiency phenotypes (all p≤0.001). African-American 
women had more maternal stress and cervical insufficiency but less decidual hemorrhage and 
placental dysfunction compared to Caucasian women (all p<0.05). Gestational age at delivery 
decreased as the number of phenotypes present increased.
Conclusions—Precise SPTB phenotyping classifies women with SPTB and identifies specific 
differences between very early and early SPTB and between African-Americans and Caucasians.
Keywords
spontaneous preterm birth; preterm phenotype; racial disparity
INTRODUCTION
Preterm birth (PTB) complicates approximately 12% of pregnancies, but is responsible for 
the majority of neonatal death and long-term morbidity amongst non-anomalous newborns 
in the United States.1,2 In recent years, clinicians and researchers have sought to identify 
causes and outline effective prematurity prevention and treatment strategies, with variable 
success. Although the overall rate of PTB has decreased slightly in the United States, this 
reduction has been mainly in late PTB; the rate of early PTB (<34 weeks gestation) has 
remained constant.3 Increased utilization of resources in early life, increased need for early 
intervention services, and reduced school performance are more common among survivors 
of preterm birth, resulting in significant societal costs.4–6
A multitude of poorly understood mechanisms are necessary for pregnancy maintenance and 
the normal transition to labor.7,8 The initiation of preterm parturition also remains poorly 
understood, but multiple potential causes and triggers are thought to result in the final 
common pathway of PTB. The phenotype of PTB refers to the biochemical and physical 
characteristics of the mother, fetus, and/or placenta that lead to, and/or are present at the 
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time of, delivery.7,9 When activated or altered prematurely any of these processes, either 
alone or in combination, may lead to premature parturition.
Many traditional PTB classification systems stratify preterm deliveries by gestational age at 
delivery (early vs. late) or general clinical presentation (e.g., spontaneous preterm labor, 
preterm premature rupture of membranes [PPROM], and iatrogenic [indicated] preterm 
birth).10,11 These classifications are broad and are unlikely to be sufficiently precise to 
define the underlying etiologies responsible for PTB.
Recently, experts have proposed more sophisticated classification systems. According to 
Goldenberg et al. the most useful classification system will incorporate antenatal factors 
(e.g. maternal infections, short cervical length, polyhydramnios), delivery clinical 
presentation (e.g., contractions, bleeding, advanced cervical dilation), and relevant 
laboratory/pathological exam findings.8 In 2012, Villar, et al. proposed a PTB phenotype 
classification that incorporates 5 components – maternal conditions, fetal conditions, 
placental conditions, signs of parturition initiation, and the pathway to delivery. However, 
this classification system has not been validated or used in practice.7
We concur that the optimal classification system should incorporate the clinical phenotype 
(defined as one or more characteristics of the mother, fetus, and/or placenta, and the delivery 
presentation) with genetic and biochemical markers.9 Due to the heterogeneous nature of 
SPTB, it is likely that more than one phenotype may be present for each individual preterm 
delivery.
We hypothesized that a comprehensive SPTB classification system could be developed to 
characterize an individual’s PTB phenotype, and this phenotype could be used to identify 
specific differences between women with early and later SPTB. Such a system could 
facilitate future attempts to identify underlying etiologies of SPTB and provide a basis for 
studies of new intervention strategies.
MATERIALS and METHODS
This is a planned analysis of a multicenter, prospectively collected case-control study of 
women enrolled in the Eunice Kennedy Shriver National Institute for Child Health and 
Human Development Genomic and Proteomic Network for Preterm Birth Research. Briefly, 
women were recruited across eight clinical sites from November 2007 through January 
2011. Cases consisted of women who delivered singleton pregnancies between 20.0–33.9 
weeks gestation following the spontaneous onset of labor (PTB cases). Women with preterm 
premature rupture of membranes (PPROM) who labored and delivered prior to 34 weeks 
were also included as cases. Women with iatrogenic or medically indicated preterm 
deliveries (e.g., due to pre-eclampsia or growth restriction) were excluded. A concomitant 
diagnosis of pre-eclampsia was not an exclusion, provided that the woman had spontaneous 
onset of preterm labor as defined above.
Clinical and demographic data were collected by trained research nurses. Research nurses 
conducted in-person interviews with participants and abstracted additional clinical and 
demographic data from medical records. Participating women were interviewed prior to 
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hospital discharge from their delivery encounter whenever possible, and all interviews were 
performed within 14 days of delivery. Data collected included demographics, medical, 
social, family, and obstetric histories, obstetric course and complications during the current 
pregnancy (including intrapartum course, mode of delivery, and neonatal outcomes). 
Women also completed questionnaires to evaluate anxiety (Beck anxiety index), depression 
(Beck depression inventory), and perceived stress (Perceived stress scale).12 In addition, 
participants were asked to indicate their attitude and the attitude of their partner with respect 
to pregnancy. This study was approved by the Institutional Review Board at each center, and 
written, informed consent was obtained from all participants.
A phenotyping tool was designed by the authors (MSE, TAM, MWV) to group maternal 
social, demographic, family history, and obstetric factors into 9 potential underlying SPTB 
categories. These categories include: (1) Infection/inflammation, (2) decidual hemorrhage, 
(3) maternal stress, (4) cervical insufficiency, (5) uterine distention, (6) placental 
dysfunction, (7) premature rupture of the membranes (PROM), (8) maternal comorbidities, 
and (9) familial factors (Table 1). Within each of the 9 categories, clinical factors were 
classified as providing strong, moderate, and possible evidence of the phenotype. Any of the 
listed criteria were sufficient for phenotype classification; it was not required that all criteria 
be met within each classification (Table 1). A phenotype profile was assigned to each 
woman by assessing whether she met criteria for each of the 9 phenotypes. Next, the 
phenotype profiles of women with very early PTB (delivering the current gestation at 20.0–
27.9 weeks gestation) were compared to those with early PTB (delivery 28.0–33.9 weeks 
gestation). Finally, we examined phenotype profiles by self-reported race/ethnicity.
Statistical analysis was performed using STATA version 12.1 (College Station, TX). 
Comparisons were made using student’s t-test, chi-square, ANOVA, and the Pearson 
correlation coefficient as appropriate.
RESULTS
The phenotyping tool (Table 1) was applied to 1025 women with SPTB <34 weeks 
gestation, including 281 with very early SPTB (20.0–27.9 weeks gestation). Basic 
demographics and baseline characteristics, compared by delivery gestational age epoch, are 
shown in Table 2. The majority of women (800, 78%) met criteria for more than one 
phenotype, although 43 (4%) had no evidence of any phenotypes (Table 3). We observed an 
inverse relationship between the number of phenotypes and gestational age at delivery, as 
those with multiple phenotypes delivered earliest (r2=−0.110, p<0.001, Table 3).
The number and percentage of women with each of the 9 clinical phenotypes, and the 
corresponding mean delivery gestational age are shown in Table 4. The maternal stress 
phenotype was most common; more than half of all women with SPTB had strong, 
moderate, or possible evidence of maternal stress. Infection/inflammation (38%), PPROM 
(35%), familial (32%), and decidual hemorrhage (31%) were the next most common 
phenotypes.
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Women with any evidence of cervical insufficiency delivered, on average, more than 2.5 
weeks earlier than those without any evidence of cervical insufficiency. Those with any 
evidence of decidual hemorrhage, and those with any evidence of inflammation or infection 
also delivered significantly earlier (1.0 weeks and 0.7 weeks, respectively) compared to 
those without evidence of the phenotype (Table 4). Women with strong evidence of decidual 
hemorrhage or cervical insufficiency delivered at the earliest gestational ages. For other 
phenotypes, women delivered later with the phenotype than without it. For example, those 
with strong evidence of maternal co-morbidities or familial phenotypes delivered between 
0.5 and 0.8 weeks later than those who did not.
The distribution of phenotypes among women with very early SPTB (20.0–27.9 weeks 
gestation) and early SPTB (28.0–33.6 weeks gestation) were compared, and several 
differences noted (Table 5). Among women with very early SPTB, the distributions of 
phenotypes differed from the overall cohort. Although maternal stress remained the most 
common phenotype (60%) and was similar between gestational age epochs, infection/
inflammation (47% vs. 35%, p<0.001) and decidual hemorrhage (39% vs. 28%, p<0.001), 
and cervical insufficiency (25% vs. 7%, p<0.001) were substantially more common among 
those with very early SPTB (all p≤0.001, Table 5).
Finally, we evaluated phenotype profiles based on self-reported race. More than 90% of 
women in this cohort were self reported African-American or Caucasian, and therefore we 
limited this portion of the analysis to these two groups. The 234 African-American women 
delivered approximately one week earlier than the 696 Caucasian women (29.2 vs. 30.2 
weeks gestation, p<0.001). Placental pathology was available for only 2 African-American 
women (compared with 176 Caucasian women, p<0.001). Therefore, placental pathology 
result information was removed from the phenotype definitions for this portion of the 
analysis (Table 6). Among the modified phenotype profiles, there were significant 
differences between African-American and Caucasian women (Table 6). African-American 
women were significantly more likely to have maternal stress, strong evidence of cervical 
insufficiency, possible evidence of PPROM, while they were less likely to have any 
evidence of decidual hemorrhage, any evidence of placental dysfunction, or moderate 
evidence of uterine distension compared to Caucasians (Table 6).
COMMENT
We have described and defined specific SPTB phenotypes, and have successfully used this 
classification system to group a large cohort of women with SPTB < 34.0 weeks gestation. 
We found that nearly all women with PTB had at least one phenotype, and the majority had 
some evidence of at least two distinct phenotypes. Additionally, we found that phenotypes 
vary with delivery gestational age and self-reported maternal race. Phenotype classification 
provides more detailed information beyond delivery gestational age.
Recently, there has been a concerted effort to develop classification system to refine the 
phenotype of SPTB. As part of the 2009 Global Alliance to Prevent Prematurity and 
Stillbirth Conference, several groups of investigators have proposed a new method for 
classifying PTB.7–9 The classifies both induced and spontaneous PTB, describes factors that 
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arise from fetal and maternal conditions, and distinguishes between preterm delivery 
following ‘idiopathic’ preterm labor vs. PPROM. Some patterns have been identified using 
this approach. For example, African-American women have been noted to have an increased 
incidence of PPROM. In contrast, idiopathic preterm labor has been found to predominate 
among Caucasian populations.13 However, the difference between SPTB due to preterm 
labor versus that due to PPROM may reflect other demographic considerations (such as 
ready access to transportation to arrive at the hospital before rupture of the membranes). 
Instead of broadly classifying women into these categories, we have sought to provide more 
specific possible etiologic explanations for seemingly ‘idiopathic’ preterm labor and 
PPROM. Although PPROM remains as one of the 9 phenotypes in our system, we have 
considered 8 other categories, which can be combined along with PPROM to characterize an 
individual’s PTB profile.
We found distinct differences when comparing phenotype profiles of African- American and 
Caucasian women. Previous studies have suggested that the racial disparity in rates of 
adverse pregnancy outcomes (namely, PTB), may be due to differences in maternal stress 
and/or inflammatory response.14,15 Indeed, our finding of differences in the incidence of the 
maternal stress phenotype between African-American and Caucasian women is consistent 
with these prior reports. We did not appreciate a difference between African-American and 
Caucasian women with regards to infectious phenotype, but were limited by the incomplete 
placental pathology data for this phenotype in particular.
From our data it is clear that multiple etiologies lead to the ultimate downstream clinical 
SPTB phenotype. Thus, we believe that previous, less specific approaches may be 
insufficient to identify groups of women who may have similar genotypic causes of PTB. 
Incomplete and/or imprecise phenotype characterization may in part explain why genetic 
(including genome wide association) studies have failed to consistently identify genetic 
factors associated with SPTB.9 We believe that our proposed phenotype definitions will 
allow clinicians and researchers to more accurately group women by possible underlying 
PTB etiology, which may facilitate future identification of group-specific interventions.8
Our study has several strengths. All women were identified and enrolled prospectively with 
standardized data collection. Enrollment of women occurred at 3 major perinatal centers in 
distinctly different geographic settings across the United States, increasing the 
generalizability of our results. SPTB was strictly defined prior to patient enrollment. We 
included only women with SPTB less than 34 weeks; capturing those premature neonates at 
highest risk for long-term sequelae of prematurity. Our phenotyping tool improves upon 
other previously proposed PTB classification systems by providing more specific 
classification, yet was applied using readily available data. The tool did not limit the 
classification of women into only one phenotype, and allowed for overlapping SPTB 
etiologies, necessary due to the complexity of the disease itself.
Our study should be interpreted with several limitations in mind. Phenotype definitions are 
complex and somewhat subjective. In some situations (e.g., family history), we elected to 
include variables traditionally considered to be ‘risk factors’ in our phenotype definitions, in 
order to group women likely to have similar etiologic determinants of PTB. Although this 
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was a planned analysis, clinical and biologic data were not collected specifically for 
phenotype classification. Clinical data were collected at delivery and in the immediate 
postpartum time period, precluding analysis of antenatal factors that could be followed 
serially (such as cervical length measurements over time). Although questionnaire 
instructions specify for participants to report average stress over the past month, our finding 
of a high proportion of women with the maternal stress phenotype may reflect the timing of 
questionnaire administration, rather than life events/general stress and anxiety in the month 
prior to birth. We were limited by the inclusion criteria of the initial cohort; for example, 
multiple gestation pregnancies would meet criteria for the uterine distension phenotype, but 
since this cohort was limited to singletons, multiples were excluded from the phenotype 
definitions. Additionally, the data available for each woman varied, and precluded a more 
complete comparison between African-American and Caucasian women. In general, 
incomplete data likely resulted in under-classification of some women, but would favor the 
null hypothesis. We were also unable to incorporate biomarkers (e.g. c-reactive protein, 
neutrophil count, inflammatory cytokines) or genotype, which have been previously 
correlated in some groups of women with SPTB.16–19
In this cohort, a relatively small number of women had evidence of cervical insufficiency. 
Given that the majority of participants did not have an antenatal cervical length assessment, 
and those with a cervical cerclage in situ were excluded from the main study, these findings 
are not unanticipated. Also, because only a small subset of women had placental pathology 
results available, there was likely under-classification of women into the inflammation/
infection and decidual hemorrhage phenotypes. Nonetheless, we found that a considerable 
proportion of women had evidence of infection/inflammation (37.9%) or decidual 
hemorrhage (30.8%), despite these limitations. Specific application of this tool prospectively 
would likely identify that cervical insufficiency, and to a lesser extent, inflammation/
infection and decidual hemorrhage, have a greater contribution to SPTB than we have found 
in the present study.
Although our classification system is more specific than prior systems, additional refinement 
will doubtless occur. Incorporation of prospective, longitudinal data collection throughout 
gestation, integration of biomarkers, and inclusion of maternal and/or fetal genetic data are 
necessary to more specifically define and distinguish each phenotype. We found that many 
women had evidence of several phenotypes; although this may reflect the multifactorial 
nature of SPTB, it is also possible that further refinement of the phenotype classification 
system may reduce these overlaps. A standardized approach to SPTB evaluation will 
provide an opportunity to enhance ongoing research and increase understanding of the 
etiology(ies) of SPTB. This tool may also be useful when applied to all women with PTB, 
regardless of indication, given the high probability of overlap between ‘spontaneous’ and 
‘iatrogenic’ prematurity.
Future research should validate these results in another patient population, and investigate 
the relationship between clinical phenotype and response to preterm birth preventative or 
treatment strategies in subsequent pregnancies. Additionally, neonatal outcomes should be 
examined by PTB phenotype. Consideration could also be given to application of the 
phenotyping tool to late preterm and/or early term deliveries to provide additional 
Manuck et al. Page 7













information regarding labor across the full spectrum of gestational ages. Additional 
consideration could be given to creating individual phenotype ‘scores,’ by assigning a 
numeric point value to individual criteria within each phenotype, this may more accurately 
determine the ‘level of evidence’ each woman demonstrates for each phenotype. Prospective 
application of this phenotyping tool will provide a basis for more accurate sub-classification 
of women who are more likely to share underlying environmental and/or genetic etiologies 
of prematurity. Future studies should also assess whether this classification tool enhances 
the ability of high throughput screens to uncover changes (e.g., gene expression) in a manner 
than uncovers genuine biology.
Acknowledgements
The National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human 
Development (NICHD), and the National Center for Advancing Translational Sciences provided grant support for 
the NICHD Genomics and Proteomics Network for Preterm Birth (GPN). While NICHD staff had input into the 
study design, conduct, analysis, and manuscript drafting, the comments and views of the authors do not necessarily 
represent the views of the NICHD.
Data collected at participating sites of the GPN were transmitted to Yale University, the data coordinating center 
(DCC) for the network, which stored, managed and analyzed the data for this study. On behalf of the GPN, Dr. 
Heping Zhang (DCC Principal Investigator) had full access to the clinical data in the study and takes responsibility 
for the integrity of the data.
We are indebted to our medical and nursing colleagues and the infants and their parents who agreed to take part in 
this study. The following investigators, in addition to those listed as authors, participated in this study:
Steering Committee Chair: Yoel Sadovsky, MD, Magee-Womens Research Institute, University of Pittsburgh, 
Pittsburgh, PA.
Eunice Kennedy Shriver National Institute of Child Health & Human Development – Uma M. Reddy, MD MPH; 
John V. Ilekis, PhD; Stephanie Wilson Archer, MA.
University of Alabama at Birmingham Health System (U01 HD50094, UL1 TR165) -- Rachel L. Copper, MSN 
CRNP; Pamela B. Files, MSN CRNP; Stacy L. Harris, BSN RN.
University of Pennsylvania (U01 HD5088) – Don A. Baldwin, PhD; Rita Leite, MD.
University of Texas Medical Branch at Galveston (U01 HD50078) – Margaret L. Zimmerle, BSN; Janet L. 
Brandon, RN MSN; Sonia Jordan, RN BSN; Angela Jones, RN BSN.
University of Utah Medical Center, Intermountain Medical Center, LDS Hospital, McKay-Dee Hospital, and Utah 
Valley Regional Medical Center (U01 HD50080) – Kelly Vorwaller, RN BSN; Sharon Quinn, RN; Valerie S. 
Morby, RN CCRP; Kathleen N. Jolley, RN BSN; Julie A. Postma, RN BSN CCRP.
Yale University School of Public Health, Collaborative Center for Statistics in Science (U01 HD50062) -- Kei-Hoi 
Cheung, PhD; Donna Losi DelBasso; Buqu Hu, MS; Hao Huang, MD MPH; Lina Jin, PhD; Analisa L. Lin, MPH; 
Charles C. Lu, MS; Lauren Perley, MA; Laura Jeanne Simone, BA; Chi Song, PhD; Feifei Xiao, PhD; Yaji Xu, 
PhD.
Alpert Medical School of Brown University, Women & Infants Hospital of Rhode Island – Dwight J. Rouse, MD 
MSPH; Donna Allard, RNC.
Columbia University Hospital, Drexel University, Christiana Care Health Systems, and St. Peter's University 
Hospital – Ronald Wapner, MD; Michelle Divito, RN MSN; Sabine Bousleiman, RN MSN MsPH; Vilmarie 
Carmona, MA; Rosely Alcon, RN BSN; Katty Saravia, MA; Luiza Kalemi, MA; Mary Talucci, RN MSN; Lauren 
Plante, MD MPH; Zandra Reid, RN BSN; Cheryl Tocci, RN BSN; Marge Sherwood; Matthew Hoffman, MD; 
Stephanie Lynch, RN; Angela Bayless, RN; Jenny Benson, RN; Jennifer Mann, RN; Tina Grossman, RN; 
Stephanie Lort, RN; Ashley Vanneman; Elisha Lockhart; Carrie Kitto; Edwin Guzman, MD; Marian Lake, RN; 
Shoan Davis; Michele Falk; Clara Perez, RN.
Manuck et al. Page 8













Northwestern University – Alan M Peaceman MD, Lara Stein RN, Katura Arego, Mercedes Ramos-Brinson B.S., 
Gail Mallett RN BSN.
University of North Carolina – John M. Thorp, Jr, MD MPH; Karen Dorman, RN MS; Seth Brody, MD MPH.
University of Texas Health Science Center at Houston and Lyndon Baines Johnson General Hospital/Harris County 
Hospital District – Sean C. Blackwell, MD; Maria Hutchinson, MPH.
GPN Advisory Board – Anthony Gregg (chair), MD, University of South Carolina School of Medicine; Reverend 
Phillip Cato, PhD; Traci Clemons, PhD, The EMMES Corporation; Alessandro Ghidini, MD, Inova Alexandria 
Hospital; Emmet Hirsch, MD, Feinberg School of Medicine, Northwestern University; Jeff Murray, MD, 
University of Iowa; Emanuel Petricoin, PhD, George Mason University; Caroline Signore, MD MPH, Eunice 
Kennedy Shriver National Institute of Child Health and Human Development; Charles F. Sing, PhD, University of 
Michigan; Xiaobin Wang, MD, Children Memorial Hospital.
References
1. Muglia LJ, Katz M. The enigma of spontaneous preterm birth. The New England journal of 
medicine. 2010; 362:529–535. [PubMed: 20147718] 
2. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of 
preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic 
analysis and implications. Lancet. 2012; 379:2162–2172. [PubMed: 22682464] 
3. Hamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2012. National vital statistics 
reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics. 
National Vital Statistics System. 2013; 62:1–20.
4. Clements KM, Barfield WD, Ayadi MF, Wilber N. Preterm birth-associated cost of early 
intervention services: an analysis by gestational age. Pediatrics. 2007; 119:e866–e874. [PubMed: 
17339387] 
5. Chambers GM, Lee E, Hoang VP, Hansen M, Bower C, Sullivan EA. Hospital utilization, costs and 
mortality rates during the first 5 years of life: a population study of ART and non-ART singletons. 
Human reproduction. 2014; 29:601–610. [PubMed: 24310618] 
6. Ahlsson F, Kaijser M, Adami J, Lundgren M, Palme M. School Performance After Preterm Birth. 
Epidemiology. 2014
7. Villar J, Papageorghiou AT, Knight HE, et al. The preterm birth syndrome: a prototype phenotypic 
classification. American journal of obstetrics and gynecology. 2012; 206:119–123. [PubMed: 
22177191] 
8. Goldenberg RL, Gravett MG, Iams J, et al. The preterm birth syndrome: issues to consider in 
creating a classification system. American journal of obstetrics and gynecology. 2012; 206:113–
118. [PubMed: 22177186] 
9. Kramer MS, Papageorghiou A, Culhane J, et al. Challenges in defining and classifying the preterm 
birth syndrome. American journal of obstetrics and gynecology. 2012; 206:108–112. [PubMed: 
22118964] 
10. Savitz DA, Blackmore CA, Thorp JM. Epidemiologic characteristics of preterm delivery: etiologic 
heterogeneity. American journal of obstetrics and gynecology. 1991; 164:467–471. [PubMed: 
1992685] 
11. Meis PJ, Ernest JM, Moore ML. Causes of low birth weight births in public and private patients. 
American journal of obstetrics and gynecology. 1987; 156:1165–1168. [PubMed: 3578431] 
12. Cohen S, Lichtenstein E. Perceived stress, quitting smoking, and smoking relapse. Health 
psychology : official journal of the Division of Health Psychology, American Psychological 
Association. 1990; 9:466–478.
13. Henderson JJ, McWilliam OA, Newnham JP, Pennell CE. Preterm birth aetiology 2004–2008. 
Maternal factors associated with three phenotypes: spontaneous preterm labour, preterm pre-
labour rupture of membranes and medically indicated preterm birth. The journal of maternal-fetal 
& neonatal medicine : the official journal of the European Association of Perinatal Medicine, the 
Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 
2012; 25:642–647.
Manuck et al. Page 9













14. Menon R, Dunlop AL, Kramer MR, Fortunato SJ, Hogue CJ. An overview of racial disparities in 
preterm birth rates: caused by infection or inflammatory response? Acta obstetricia et 
gynecologica Scandinavica. 2011; 90:1325–1331. [PubMed: 21615712] 
15. Catov JM, Flint M, Lee M, Roberts JM, Abatemarco DJ. The Relationship Between Race, 
Inflammation and Psychosocial Factors Among Pregnant Women. Maternal and child health 
journal. 2014
16. Kim MA, Lee BS, Park YW, Seo K. Serum markers for prediction of spontaneous preterm delivery 
in preterm labour. European journal of clinical investigation. 2011; 41:773–780. [PubMed: 
21299551] 
17. Kim MA, Lee YS, Seo K. Assessment of predictive markers for placental inflammatory response 
in preterm births. PloS one. 2014; 9:e107880. [PubMed: 25291377] 
18. Ruiz RJ, Jallo N, Murphey C, Marti CN, Godbold E, Pickler RH. Second trimester maternal 
plasma levels of cytokines IL-1Ra, Il-6 and IL-10 and preterm birth. Journal of perinatology : 
official journal of the California Perinatal Association. 2012; 32:483–490. [PubMed: 22460542] 
19. Kramer MS, Kahn SR, Platt RW, et al. Mid-trimester maternal plasma cytokines and CRP as 
predictors of spontaneous preterm birth. Cytokine. 2010; 49:10–14. [PubMed: 19783155] 
Manuck et al. Page 10

























Manuck et al. Page 11
Table 1
Spontaneous preterm birth clinical phenotype classification system.
Phenotype Strong Evidence Moderate Evidence Possible Evidence
Infection / Inflammationa - Histologic 
chorioamnionitis or 
funisitis
- Positive placental 
culture or presence 






- Placental pathology 




























Decidual Hemorrhagea - Hemosiderin 
deposits or tightly 
adherent clot on 
placental pathology
- At least 25% 
hemorrhage on fetal 
or maternal interface 
on placental 
pathology




hemorrhage on fetal or 
maternal interface
- Active vaginal 
bleeding plus at least 
one of the following -
non-reassuring fetal 
heart tones, uterine 
tenderness, or uterine 
tachysystole
- Clinical diagnosis of 
abruption requiring 
delivery
- Trauma to abdomen 
or motor vehicle 
accident during 
pregnancy










- Beck Depression 
Index score indicates 
severe depression
- Perceived stress score 









- Illicit drug use or 
current binge 
alcohol use during 
pregnancy
- High risk 
socioeconomic risk 
factor: income less 
than poverty level, 
less than a high 
school degree
Cervical Insufficiency - Cervical dilation ≥2 
cm prior to 28 weeks 
- Cervical length <1.50 
cm prior to 28 weeks 
- Cervical length 
1.50–2.50 cm prior 
to 28 weeks 
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Phenotype Strong Evidence Moderate Evidence Possible Evidence
gestation in the 
absence of labor
Cervical length <0.5 cm 
prior to 28 weeks in the 
absence of labor
At least one pregnancy loss prior 
to 24 weeks gestation due to 
painless cervical dilation
gestation in the 
absence of labor
- Cervical length 1.50–
2.5cm prior to 28 




gestation in the 
absence of labor
- History of cervical 
conization 
procedure or loop 
electro-excision 
procedure
Uterine Distensiona n/a - Polyhydramnios (4-
quadrant AFI >25cm 
or single deepest 
pocket >8cm)





- Placental weight 
>90% for 
gestational age
Placental Dysfunctiona - Birthweight <3% for 
gestational age and 
gender
- Placental weight 
<3% for gestational 
age
- At least 25% 
placental infarction 
on pathology
- Reverse end diastolic
- Birthweight <10% for 
gestational age and 
gender
- Placental weight 
<10% for gestational 
age
- Absent end diastolic 
flow on cord Doppler 
prior to delivery
- Any placental 
infarction with no 
percentage listed or 
<25% on placental 
pathology
- Four quadrant 
amniotic fluid index 
<5cm or single 
deepest pocket <2cm 
on ultrasound
- Pre-eclampsia without 
severe features











test, or amnisure at 
least 48 hours prior 
to the onset of labor
- Preterm, premature 
rupture of membranes 
diagnosed with sterile 
speculum 
examination, dye test, 
or amnisure 12–48 
hours prior to the 
onset of labor
- History of PPROM 
and delivery less 
than 37 weeks in a 
prior pregnancy
Maternal Co-morbidities - Class B or higher 
diabetes mellitus
- Chronic hypertension




- Chronic renal failure 
or insufficiency
- Gestational diabetes in 
the current gestation
- Other medical 
condition affecting a 
major organ system, 
not otherwise 






Familial - At least one first 
degree relative with 
history of 
- At least one first 
degree relative with 
history of medically 
indicated preterm birth
- At least one second 
degree relative with 
history of medically 
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Phenotype Strong Evidence Moderate Evidence Possible Evidence
spontaneous preterm 
birth
- At least one second 
degree relative with 





Placental pathology was available for only 195 women (19%). When pathologic evidence of each phenotype was noted, it was included in the 
classification. The frequency of placental pathology availability did not vary with gestational age epoch.
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Table 2

























Hispanic ethnicity 63 (22.4) 148 (19.9) 0.372
Married (n, %) 122 (43.4) 390 (52.4) 0.010
Nulliparous (n, %) 141 (50.2) 340 (45.7) 0.200
Prior preterm delivery <37 weeks gestation (n, %) 69 (24.6) 222 (29.8) 0.094
Maternal pre-pregnancy BMI (kg/m2, mean +/− SD) 27.1 (7.2) 25.4 (6.5) <0.001
Cigarette use during pregnancy 54 (19.2) 138 (18.6) 0.807
Delivery gestational age, weeks (mean +/− SD) 25.5 (1.6) 31.7 (1.7) <0.001
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Table 3







0 43 (4.2) 30.7 (3.2)
1 182 (17.8) 30.5 (2.9)
2 273 (26.6) 30.1 (3.3)
3 296 (28.9) 29.9 (3.2)
4 148 (14.4) 29.5 (3.3)
5 64 (6.2) 29.8 (3.3)
6 15 (1.5) 28.4 (3.0)
7 4 (0.4) 30.5 (2.7)
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Table 4
Percentage of cases with some evidence of each of the 9 proposed phenotypes, and mean delivery gestational 





















  Strong Evidence 86 (8.4) 29.1 (3.4) 30.1 (3.2) 0.006
  Moderate Evidence 98 (9.6) 28.3 (3.6) 30.2 (3.1) <0.001
  Possible Evidence 272 (26.5) 29.9 (3.2) 30.0 (3.2) 0.620
  Any Evidence 388 (37.9) 29.6 (3.4) 30.3 (3.1) <0.001
Decidual Hemorrhage
  Strong Evidence 4 (0.4) 27.6 (4.0) 30.0 (3.2) 0.131
  Moderate Evidence 150 (14.6) 29.4 (3.4) 30.1 (3.2) 0.008
  Possible Evidence 202 (19.7) 29.1 (3.5) 30.2 (3.1) <0.001
  Any Evidence 316 (30.8) 29.3 (3.5) 30.3 (3.1) <0.001
Maternal Stress
  Strong Evidence 47 (4.6) 31.3 (2.7) 29.9 (3.2) 0.005
  Moderate Evidence 306 (29.9) 30.1 (3.3) 30.0 (3.2) 0.646
  Possible Evidence 422 (41.2) 29.6 (3.2) 30.3 (3.2) 0.001
  Any Evidence 580 (56.6) 29.8 (3.2) 30.2 (3.2) 0.081
Cervical insufficiency
  Strong Evidence 68 (6.6) 27.1 (2.6) 30.2 (3.2) <0.001
  Moderate Evidence 51 (5.0) 28.2 (2.7) 30.1 (3.2) <0.001
  Possible Evidence 22 (2.2) 28.0 (2.5) 30.0 (3.2) 0.003
  Any Evidence 119 (11.6) 27.7 (2.7) 30.3 (3.2) <0.001
Uterine distension
  Strong Evidence -- -- -- --
  Moderate Evidence 175 (17.1) 30.2 (2.8) 30.0 (3.3) 0.448
  Possible Evidence 43 (4.2) 30.3 (3.0) 30.0 (3.2) 0.539
  Any Evidence 212 (20.7) 30.2 (2.9) 30.0 (3.3) 0.418
Placental dysfunction
  Strong Evidence 39 (3.8) 30.8 (3.0) 30.0 (3.2) 0.114
  Moderate Evidence 84 (8.2) 30.2 (3.4) 30.0 (3.2) 0.643
  Possible Evidence 55 (5.4) 30.2 (3.3) 30.0 (3.2) 0.639
  Any Evidence 122 (11.9) 30.0 (3.4) 30.0 (3.2) 0.855
PPROM
  Strong Evidence 211 (20.6) 30.0 (3.0) 30.0 (3.3) 0.950

































  Moderate Evidence 141 (149 30.6 (3.2) 29.9 (3.2) 0.014
  Possible Evidence 49 (4.8) 29.7 (3.0) 30.0 (3.2) 0.440
  Any Evidence 362 (35.3) 30.2 (3.1) 29.9 (3.3) 0.078
Maternal Co-morbidities
  Strong Evidence 87 (8.5) 30.7 (2.7) 29.9 (3.3) 0.029
  Moderate Evidence 182 (17.8) 30.4 (3.1) 29.9 (3.2) 0.040
  Possible Evidence -- -- -- --
  Any Evidence 216 (21.1) 30.3 (3.1) 29.9 (3.2) 0.102
Familial
  Strong Evidence 227 (22.2) 30.4 (3.0) 29.9 (3.3) 0.023
  Moderate Evidence 143 (14.0) 29.9 (3.4) 30.0 (3.2) 0.801
  Possible Evidence -- -- -- --
  Any Evidence 331 (32.3) 30.2 (3.2) 29.9 (3.2) 0.113
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Table 5















  Strong Evidence 33 (11.7) 53 (7.1) 0.017
  Moderate Evidence 48 (17.1) 50 (6.7) <0.001
  Possible Evidence 83 (29.5) 189 (25.4) 0.181
  Any Evidence 131 (46.6) 257 (34.5) <0.001
Decidual Hemorrhage
  Strong Evidence 3 (1.1) 1 (0.13) 0.033
  Moderate Evidence 50 (17.8) 100 (13.4) 0.079
  Possible Evidence 76 (27.1) 126 (16.9) <0.001
  Any Evidence 109 (38.8) 207 (27.8) 0.001
Maternal Stress
  Strong Evidence 8 (2.9) 39 (5.2) 0.102
  Moderate Evidence 80 (28.5) 226 (30.4) 0.552
  Possible Evidence 132 (47.0) 290 (39.0) 0.020
  Any Evidence 168 (59.8) 412 (55.4) 0.204
Cervical insufficiency
  Strong Evidence 49 (17.4) 19 (2.6) <0.001
  Moderate Evidence 25 (8.9) 26 (3.5) <0.001
  Possible Evidence 11 (3.9) 11 (1.5) 0.016
  Any Evidence 70 (24.9) 49 (6.6) <0.001
Uterine distension
  Strong Evidence -- -- --
  Moderate Evidence 49 (17.4) 126 (16.9) 0.849
  Possible Evidence 10 (3.6) 33 (4.4) 0.532
  Any Evidence 58 (20.6) 154 (20.7) 0.984
Placental dysfunction
  Strong Evidence 8 (2.9) 31 (4.2) 0.325
  Moderate Evidence 23 (8.2) 61 (8.2) 0.994
  Possible Evidence 14 (5.0) 41 (5.5) 0.738
  Any Evidence 33 (11.7) 89 (12.0) 0.923
PPROM
  Strong Evidence 52 (18.5) 159 (21.4) 0.311
  Moderate Evidence 32 (11.4) 109 (14.7) 0.176



























  Possible Evidence 14 (5.0) 35 (4.7) 0.852
  Any Evidence 86 (30.6) 276 (37.1) 0.052
Maternal Co-morbidities
  Strong Evidence 14 (5.0) 73 (9.8) 0.013
  Moderate Evidence 36 (12.8) 146 (19.6) 0.011
  Possible Evidence -- -- --
  Any Evidence 46 (16.4) 170 (22.9) 0.023
Familial
  Strong Evidence 51 (18.2) 176 (23.7) 0.058
  Moderate Evidence 41 (14.6) 102 (13.67 0.716
  Possible Evidence -- -- --
  Any Evidence 84 (29.9) 247 (33.2) 0.313
None of the above phenotypes 8 (2.9) 35 (4.7) 0.186
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Table 6








  Strong Evidencea -- -- --
  Moderate Evidenceb 12 (5.1) 56 (8.1) 0.138
  Possible Evidence 65 (27.8) 176 (25.3) 0.452
  Any Evidenceb 75 (32.1) 217(31.2) 0.803
Decidual Hemorrhage
  Strong Evidencea -- -- --
  Moderate Evidenceb 20 (8.6) 56 (8.1) 0.809
  Possible Evidence 31 (13.3) 156 (22.4) 0.002
  Any Evidenceb 49 (20.9) 243 (34.9) <0.001
Maternal Stress
  Strong Evidence 1 (0.4) 45 (6.5) <0.001
  Moderate Evidence 68 (29.1) 211 (30.3) 0.717
  Possible Evidence 128 (54.7) 243 (34.9) <0.001
  Any Evidence 154 (65.8) 365 (52.4) <0.001
Cervical insufficiency
  Strong Evidence 24 (10.3) 39 (5.6) 0.014
  Moderate Evidence 14 (6.0) 34 (4.9) 0.511
  Possible Evidence 3 (1.3) 16 (2.3) 0.342
  Any Evidence 36 (15.4) 74 (10.6) 0.051
Uterine distension
  Strong Evidence -- -- --
  Moderate Evidence 25 (10.7) 130 (18.7) 0.005
  Possible Evidenceb 10 (4.3) 5 (0.7) <0.001
  Any Evidenceb 35 (15.0) 134 (19.3) 0.140
Placental dysfunction
  Strong Evidenceb 0 (0) 4 (0.6) 0.245
  Moderate Evidenceb 9 (3.9) 19 (2.7) 0.387
  Possible Evidenceb 0 (0) 32 (4.6) 0.001
  Any Evidenceb 9 (3.9) 53 (7.6) 0.046
PPROM
  Strong Evidence 48 (20.5) 145 (20.8) 0.917
  Moderate Evidence 35 (15.0) 93 (13.4) 0.540




















  Possible Evidence 17 (7.3) 27 (3.9) 0.035
  Any Evidence 85 (36.3) 245 (35.2) 0.756
Maternal Co-morbidities
  Strong Evidence 24 (10.3) 50 (7.2) 0.133
  Moderate Evidence 35 (15.0) 127 (18.3) 0.251
  Possible Evidence -- -- --
  Any Evidence 50 (21.4) 144 (20.7) 0.825
Familial
  Strong Evidence 60 (25.6) 149 (21.4) 0.180
  Moderate Evidence 38 (16.2) 90 (12.9) 0.204
  Possible Evidence -- -- --
  Any Evidence 86 (36.8) 216 (31.0) 0.106
None of the above phenotypes 11 (4.7) 30 (4.3) 0.801
a
This category relies entirely on placental pathology data, and a disproportionate amount of missing data were present for African-American 
women, therefore this comparison could not be made.
b
Calculated without placental pathology data in definition.
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